Vepdegestrant Results in Longer PFS Than Fulvestrant in Previously Treated Patients with ESR1-mutated, ER-positive, HER2-negative ABC By Ogkologos - June 4, 2025 683 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VERITAC-2 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Cancer Immunotherapy Drug Simultaneously Targets Two Proteins that Block Immune Response April 4, 2018 NHS England change of chief executive – what does it mean... August 19, 2021 EMA Recommends Granting a Marketing Authorisation for Generic Abiraterone for the... March 8, 2021 Treatment for Children with Leukemia Also Effective for Adolescents, Young Adults February 25, 2019 Load more HOT NEWS “Mi corazón siempre dolerá”: Cómo honro a mi mejor amiga de... Radiation-Induced ‘Genomic Scars’ Associate with Poor Patient Outcome Community Surprises Teen Battling Bone Cancer With Brand New Car For... Ivosidenib and Azacitidine Combination Shows Significant Clinical Benefit in Patients with...
